MedTrace Logo

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

NCT04879043 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-07-24

No results posted yet for this study

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Conditions

Interventions

DRUG

HDP-101

HDP-101 is available as lyophilized white powder for preparation of infusion.

Sponsors & Collaborators

  • Heidelberg Pharma AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2025-08-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Hungary
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879043 on ClinicalTrials.gov